Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 896

Results For "Pan"

9139 News Found

Zydus Cadila receives tentative approval from USFDA for lung cancer drugs
Policy | June 03, 2021

Zydus Cadila receives tentative approval from USFDA for lung cancer drugs

Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors


Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg
News | June 02, 2021

Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.


Progress on new ventures key for Aurobindo Pharma: ICICI Securities
News | June 02, 2021

Progress on new ventures key for Aurobindo Pharma: ICICI Securities

Aurobindo has one of the most enduring generics ecosystems among peers


Lasa Supergenerics FY21 profit up 521%
News | June 02, 2021

Lasa Supergenerics FY21 profit up 521%

Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%


Shilpa Medicare Q4FY21 consolidated PAT at Rs. 7.82 Cr
News | June 01, 2021

Shilpa Medicare Q4FY21 consolidated PAT at Rs. 7.82 Cr

The company has posted net profit of Rs.147.78 crores for the 12 months period ended March 31, 2021


Marksans Pharma Q4 FY21 profit up 86%
News | June 01, 2021

Marksans Pharma Q4 FY21 profit up 86%

The company's operating revenue for Q4 FY21 was Rs. 330.2 crore


Unilever to launch recyclable tubes for oral care in India
Packaging | June 01, 2021

Unilever to launch recyclable tubes for oral care in India

EPL will supply APR approved 100% recyclable and fully sustainable Platina Tubes for the toothpaste category of Unilever


Aurobindo Pharma Q4FY21 consolidated net profit at Rs. 801.58 Cr
News | May 31, 2021

Aurobindo Pharma Q4FY21 consolidated net profit at Rs. 801.58 Cr

The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021


Margins impacted by high expenses for Pfizer: ICICI Securities
News | May 31, 2021

Margins impacted by high expenses for Pfizer: ICICI Securities

Adjusted PAT declined 18.8% YoY


Cadila Healthcare’s margin supported by lower R&D : ICICI Securities
Drug Approval | May 31, 2021

Cadila Healthcare’s margin supported by lower R&D : ICICI Securities

India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact